Human Growth Hormone-Releasing Factor (hGRF)1–29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog
Authors:
- Roger LégerRLRoger Léger
- Karen ThibaudeauKTKaren Thibaudeau
- Corinne BenquetCBCorinne Benquet
- Martin RobitailleMRMartin Robitaille
- Isabelle PellerinIPIsabelle Pellerin
- Véronique ParadisVPVéronique Paradis
- Pieter van WykPWPieter van Wyk
- Khan PhamKPKhan Pham
- Dominique P. BridonDBDominique P. Bridon
- 1 July 2005
- journal article
- Published by The Endocrine Society in Endocrinology
- Vol. 146 (7) , 3052-3058
Abstract
In vivo bioconjugation to the free thiol on Cys34 of serum albumin by a strategically placed reactive group on a bioactive peptide is a useful tool to extend plasma half-life. Three maleimido derivates of human GH-releasing factor (hGRF)1–29 were synthesized and bioconjugated to human serum albumin ex vivo. All three human serum albumin conjugates showed enhanced in vitro stability against dipeptidylpeptidase-IV and were bioactive in a GH secretion assay in cultured rat anterior pituitary cells. When the maleimido derivatives were individually administered sc to normal male Sprague Dawley rats, an acute secretion of GH was measured in plasma. The best compound, CJC-1295, showed a 4-fold increase in GH area under the curve over a 2-h period compared with hGRF1–29. CJC-1295, a tetrasubstituted form of hGRF1–29 with an added Nε-3-maleimidopropionamide derivative of lysine at the C terminus, was selected for further pharmacokinetic evaluation, where it was found to be present in plasma beyond 72 h. A Western blot analysis of the plasma of a rat injected with CJC-1295 showed the presence of a CJC-1295 immunoreactive species on the band corresponding to serum albumin, appearing after 15 min and remaining in circulation beyond 24 h. These results led to the identification of CJC-1295 as a stable and active hGRF1–29 analog with an extended plasma half-life.Keywords
This publication has 31 references indexed in Scilit:
- Identification of CJC-1131-albumin bioconjugate as a stable and bioactive GLP-1(7–36) analogBioorganic & Medicinal Chemistry Letters, 2004
- Pharmacodynamic evaluation of a PEGylated analogue of human growth hormone releasing factor in rats and pigsGrowth Hormone & IGF Research, 2004
- PEGylation of growth hormone-releasing hormone (GRF) analoguesAdvanced Drug Delivery Reviews, 2003
- Development and Characterization of a Glucagon-Like Peptide 1-Albumin ConjugateDiabetes, 2003
- Maleimide-oligo(ethylene glycol) Derivatives of Camptothecin as Albumin-Binding Prodrugs: Synthesis and Antitumor EfficacyBioconjugate Chemistry, 2003
- Probing the Cysteine-34 Position of Endogenous Serum Albumin with Thiol-Binding Doxorubicin Derivatives. Improved Efficacy of an Acid-Sensitive Doxorubicin Derivative with Specific Albumin-Binding Properties Compared to That of the Parent CompoundJournal of Medicinal Chemistry, 2002
- A Novel Macromolecular Prodrug Concept Exploiting Endogenous Serum Albumin as a Drug Carrier for Cancer ChemotherapyJournal of Medicinal Chemistry, 2000
- Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus.Journal of Clinical Investigation, 1986
- Growth Hormone-Releasing Hormone*Endocrine Reviews, 1986
- Pulsatile growth hormone secretion in normal man during a continuous 24-hour infusion of human growth hormone releasing factor (1-40). Evidence for intermittent somatostatin secretion.Journal of Clinical Investigation, 1985